PSMA PET for BCR Salvage RT Management: Projecting Survival Data and Additional Research Avenues

Drs. Jérémie Calais, Amar Kishan, and Nicholas Nickols, all of the University of California, Los Angeles, continue discussing their phase 3 trial on the impact of PSMA PET/CT on prostate cancer salvage radiotherapy management, including expectations for the study’s final data readout in 2025 as well as the research avenues that are suggested by the initial findings.

They consider whether they expect a difference in EFS, MFS, and OS if patients are followed for 10 more years, as well as how future studies might build upon or validate the initial findings of this one.

View their previous comments on the Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management.